A2A Pharmaceuticals, Inc.'s Form 4 filing
Biomea Fusion, Inc. (BMEA) · filed Apr 6, 2023
- Accession no.
- 0001859061-23-000002
- Filed
- Apr 6, 2023
- Trade date
- Mar 31, 2023
- Filing delay
- 6 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $6.25M. It was filed 6 days after the trade, past the 2-business-day deadline.
This filing was later replaced by the amendment 0001859061-23-000003 (Apr 6, 2023). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| A2A Pharmaceuticals, Inc.CIK 0001859061 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2023 | Common Stock | SSaleAcquired | +200,000 | $31.25F1 | +$6,250,000 | 4,100,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
A total of 200,000 shares were sold at an average price of 31.25 in multiple transactions ranging in price from 30.87 to 31.64
Referenced by the price of 1 transaction in Table I.